Oral Administration of Semicarbazide Limits Weight Gain together with Inhibition of Fat Deposition and of Primary Amine Oxidase Activity in Adipose Tissue

Table 1

Tissue distribution of semicarbazide-sensitive amine oxidase activity in control mice.

Tissue	Semicarbazide-inhibited oxidation of 0.1 mM benzylamine; (nmoles/mg protein/min)
Visceral WAT	4.402 ± 0.368 (8)
Subcutaneous WAT	2.250 ± 0.144 (4)
Interscapular brown fat	0.860 ± 0.027 (4)
Aorta	0.506 ± 0.064 (10)
Duodenum	0.201 ± 0.018 (4)
Kidney	0.018 ± 0.005 (10)

Homogenates were preincubated for 15 min without or with 1 mM semicarbazide before a 30-minute incubation in the presence of 0.1 mM [¹⁴C]-benzylamine. The semicarbazide-inhibited oxidation is representative of the SSAO activity. Mean ± SEM of the number of determinations indicated in parentheses. Analysis of variance showed that the factor tissue was highly influencing SSAO activity (𝑃<10⁻¹⁸).